Literature DB >> 14634792

L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.

Masahito Tsurusawa1, Motoaki Chin, Asayuki Iwai, Keiko Nomura, Hideaki Maeba, Takashi Taga, Takeshi Higa, Tomoko Kuno, Toshinori Hori, Akiko Muto, Miyo Yamagata.   

Abstract

PURPOSE: To determine the minimum levels of L-asparaginase (ASNase) activity necessary to maintain L-asparagine (Asn) depletion under ASNase treatment in acute lymphoblastic leukemia (ALL).
METHODS: We measured ASNase activity using an enzyme coupling method with a limit of detection of 2 U/l and examined the relationship between ASNase activity and Asn levels in blood samples from 14 children with ALL.
RESULTS: In all but one patient showing high ASNase antibody titers, minimum ASNase activity to maintain Asn depletion levels below the limit of detection (40 ng/ml) ranged from 6 to 180 U/l with a median value of 16 U/l. In 11 patients, the enzyme activity corresponding to minimum detectable Asn levels ranged from 2 to 32 U/l with a median value of 6.5 U/l. Patients with an ASNase activity of 2 U/l or an undetectable activity (<2 U/l) had nearly normal Asn levels: 4140+/-1161 ng/ml at 2 U/l and 7235+/-3107 ng/ml at <2 U/l (mean+/-SD). Statistical analysis showed that ASNase activity in the range of 2-32 U/l was inversely correlated with Asn levels ( r=-0.803, P=0.001).
CONCLUSION: These results show that Asn levels are strongly correlated with plasma ASNase activity even at low enzyme activities (<50 U/l) and that this sensitive ASNase assay can be used to estimate plasma Asn depletion levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634792     DOI: 10.1007/s00280-003-0734-5

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

Review 1.  Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.

Authors:  Xavier Thomas; Caroline Le Jeune
Journal:  Int J Hematol Oncol       Date:  2016-05-05

2.  6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1.

Authors:  Bifeng Yuan; Jing Zhang; Hongxia Wang; Lei Xiong; Qian Cai; Tina Wang; Steven Jacobsen; Sriharsa Pradhan; Yinsheng Wang
Journal:  Cancer Res       Date:  2011-01-14       Impact factor: 12.701

3.  Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

Authors:  Wanda L Salzer; Barbara Asselin; Jeffrey G Supko; Meenakshi Devidas; Nicole A Kaiser; Paul Plourde; Naomi J Winick; Gregory H Reaman; Elizabeth Raetz; William L Carroll; Stephen P Hunger
Journal:  Blood       Date:  2013-06-05       Impact factor: 22.113

4.  A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL).

Authors:  Suja Johnson; Chetan Dhamne; Hari Sankaran; Khushboo A Gandhi; Pallavi Rane; Nirmaly Roy Moulik; Shraddha Mahesh Jadhav; Murari Gurjar; Gaurav Narula; Shripad Banavali; Vikram Gota
Journal:  Cancer Chemother Pharmacol       Date:  2022-10-17       Impact factor: 3.288

5.  The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia.

Authors:  Shizuka Watanabe; Kumiko Miyake; Chitose Ogawa; Haruna Matsumoto; Kenichi Yoshida; Shinsuke Hirabayashi; Daisuke Hasegawa; Tadao Inoue; Junko Kizu; Reiko Machida; Akira Ohara; Ryota Hosoya; Atsushi Manabe
Journal:  Int J Hematol       Date:  2009-09-19       Impact factor: 2.490

6.  Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors FcεRI and FcγRIII.

Authors:  Sanjay Rathod; Manda Ramsey; Mary V Relling; Fred D Finkelman; Christian A Fernandez
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941

7.  Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model.

Authors:  Robin Q H Kloos; Ron Mathôt; Rob Pieters; Inge M van der Sluis
Journal:  Haematologica       Date:  2021-05-01       Impact factor: 9.941

8.  Targeting Asparagine and Serine Metabolism in Germinal Centre-Derived B Cells Non-Hodgkin Lymphomas (B-NHL).

Authors:  Zuhal Eraslan; Grigorios Papatzikas; Jean-Baptiste Cazier; Farhat L Khanim; Ulrich L Günther
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

9.  Hypoglycemia associated with L-asparaginase in acute lymphoblastic leukemia treatment: a case report.

Authors:  Ryuma Tanaka; Tomoo Osumi; Masashi Miharu; Tomohiro Ishii; Tomonobu Hasegawa; Takao Takahashi; Hiroyuki Shimada
Journal:  Exp Hematol Oncol       Date:  2012-04-19

10.  Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia.

Authors:  Stefano Tiziani; Yunyi Kang; Ricky Harjanto; Joshua Axelrod; Carlo Piermarocchi; William Roberts; Giovanni Paternostro
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.